Welcome to MedArena!

Your trusted destination for CME, CPD & Medical Education across the Middle East.

Information

  • Address:MedArena Corporation
  • Call Us:1 (800) 828-2059
  • Email:support [at] medarenaevents.com
Dr. Catherine Bollard

Achievements

2025Appointed Senior Vice President and Chief Research Officer of Children's National.
—Served as Director of the Center for Cancer and Immunology Research.
—Served as President of the Foundation for the Accreditation of Cellular Therapy (FACT).

Dr. Catherine Bollard

SVP & Chief Research Officer

Children's National Hospital

About

Dr. Catherine Bollard is a physician-scientist and internationally recognized leader in cancer immunology, cellular therapy and pediatric oncology. She serves as Senior Vice President and Chief Research Officer at Children's National, Director of the Center for Cancer and Immunology Research, and Professor at George Washington University. Her research focuses on immune-based treatments for cancer, viral infections and immune deficiencies, including adoptive T-cell therapies and genetically modified cell therapies. She has been continuously NIH-funded for more than a decade and has peer-reviewed more than 200 publications. She has also held leadership roles within the cellular-therapy field and served as Editor in Chief of Blood Advances.

Full Professional Biography

Full Name: Catherine Mary Bollard, MBChB, MD

Specialty: Pediatric Hematology, Immunology, and Cellular Immunotherapy

Current Institution: Children's National Hospital, Washington, D.C.

Current Leadership Position: Senior Vice President and Chief Research Officer, Children's National

Additional Positions: Director of the Center for Cancer and Immunology Research; Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine at George Washington University

Research Focus: Cancer immunotherapy, T-cell therapy, cell and gene therapies, stem cell transplantation, viral infections, and immune deficiencies.

Dr. Catherine Mary Bollard is an internationally recognized physician-scientist and a leading researcher in cellular immunotherapy, pediatric oncology, and immunology. Her work focuses on developing innovative treatments that harness the body's immune system to fight cancer, viral infections, and diseases associated with weakened immune function.

She serves as Senior Vice President and Chief Research Officer at Children's National Hospital in Washington, D.C., where she leads research strategy and supports the development of basic, translational, and clinical research programs. She also directs the Center for Cancer and Immunology Research and holds professorial appointments at George Washington University School of Medicine and Health Sciences.

Born and raised in New Zealand, Dr. Bollard completed her medical education at the University of Otago. She subsequently undertook specialist training in pediatrics and hematology, developing expertise in bone marrow transplantation, immunology, and the treatment of patients with cancer and immune deficiencies.

Her interest in developing safer cancer treatments was influenced by the experience of a close friend who developed treatment-related leukemia following therapy for Hodgkin lymphoma. This experience helped shape her commitment to developing treatments that target cancer cells while minimizing damage to healthy tissues.

In 2000, Dr. Bollard moved to the United States to pursue research into T-cell therapies for cancer, particularly cancers associated with the Epstein–Barr virus (EBV). She joined Baylor College of Medicine and Texas Children's Hospital, where she progressed to become a tenured professor and established a strong research background in cellular therapies and transplantation medicine.

Her research has focused on virus-specific T cells, which can recognize and eliminate infected cells, as well as tumor-specific T cells designed to target malignant cells. These approaches have particular relevance for patients whose immune systems have been weakened by chemotherapy or stem cell transplantation.

In 2013, Dr. Bollard joined Children's National Hospital and George Washington University, where she continued developing clinical and translational research programs. She has helped advance experimental cellular therapies for patients with cancer, post-transplant viral infections, and underlying immune deficiencies.

Her work also extends to HIV research, including investigations into whether engineered or selected immune cells can contribute to long-term viral control and potential strategies toward a functional cure. In addition, her research programs investigate cellular therapies for conditions associated with cytomegalovirus, adenovirus, BK virus, and other infections that can cause serious complications in immunocompromised patients.

Dr. Bollard has held prominent leadership positions in professional organizations and research institutions. She is a past president of the International Society for Cell & Gene Therapy, formerly known as the International Society of Cellular Therapy, and has served as president of the Foundation for the Accreditation of Cellular Therapy (FACT). She has also contributed to scientific oversight through advisory and review committees associated with the U.S. Food and Drug Administration and the National Cancer Institute.

As an academic researcher, she has authored more than 200 peer-reviewed publications and has led numerous investigator-initiated clinical studies involving immune-based therapies. Her contributions have helped advance the translation of laboratory discoveries into clinical research for children and adults with serious diseases.

Dr. Bollard's career brings together clinical medicine, laboratory science, clinical trials, and research leadership. Her work continues to contribute to the development of more targeted and potentially less toxic treatments for cancer, while expanding the possibilities of cellular immunotherapy for patients with limited treatment options.

Full Achievement Timeline

1986–1991 — Medical Education at the University of Otago

  • Studied medicine at the University of Otago in Dunedin, New Zealand.
  • Earned her Bachelor of Medicine and Bachelor of Surgery (MBChB).
  • Established the medical foundation for her subsequent career in pediatrics, hematology, and immunotherapy.

1995–2002 — Specialist Training in Pediatrics

  • Undertook specialist training in pediatrics in New Zealand.
  • Obtained specialist qualifications through the Royal Australasian College of Physicians.
  • Developed expertise in the care of children with serious illnesses, including cancer and disorders affecting the immune system.

1998–2002 — Specialist Training in Hematology

  • Completed specialist training in hematology through the Royal College of Pathologists of Australasia.
  • Developed clinical expertise in blood disorders, hematologic malignancies, and complications associated with bone marrow transplantation.
  • Built the clinical foundation for her subsequent research into cellular immunotherapy.

2000 — Moved to the United States to Advance T-Cell Therapy Research

  • Relocated to the United States to pursue research into immune-based cancer treatments.
  • Joined the research environment at Baylor College of Medicine and Texas Children's Hospital.
  • Began developing T-cell therapies targeting EBV-associated malignancies, including Hodgkin lymphoma.
  • Helped advance an emerging field focused on using immune cells to identify and attack cancer cells.

2000–2004 — Doctor of Medicine Research Degree

  • Completed her Doctor of Medicine (MD) degree at the University of Otago, with research in immunology.
  • Strengthened her expertise in immune mechanisms relevant to cancer treatment and cellular therapies.

2000s — Advanced Cellular Immunotherapy Research at Baylor College of Medicine

  • Progressed through academic and research positions at Baylor College of Medicine.
  • Contributed to the development of virus-specific T-cell therapies for patients with cancer and those experiencing complications after transplantation.
  • Helped advance research translating laboratory findings into clinical studies.
  • Developed expertise in clinical trials involving cellular immunotherapy.

2010–2018 — Board Member, Foundation for the Accreditation of Cellular Therapy

  • Served on the board of directors of the Foundation for the Accreditation of Cellular Therapy.
  • Contributed to professional oversight and initiatives supporting quality and standards in cellular therapy.
  • Participated in the broader development of the field as cellular therapies became increasingly important in transplantation and cancer treatment.

2012–2020 — Chair of the Non-Hodgkin Lymphoma Committee, Children's Oncology Group

  • Chaired the Non-Hodgkin Lymphoma Committee of the Children's Oncology Group.
  • Contributed to research coordination and the development of clinical research priorities for pediatric non-Hodgkin lymphoma.
  • Supported collaborative efforts to improve understanding and treatment of childhood lymphomas.

2013 — Joined Children's National Hospital and George Washington University

  • Joined Children's National and George Washington University after her tenure at Baylor College of Medicine.
  • Continued developing clinical and translational research programs in cellular immunotherapy.
  • Expanded research into cancer, immune deficiencies, and viral infections affecting children and adults.
  • Established a long-term research program focused on translating innovative immune-based treatments into clinical applications.

2014 — Became Associate Editor of the Journal Blood

  • Began serving as an associate editor of Blood, a leading hematology research journal.
  • Contributed to the evaluation and dissemination of scientific research in hematology and related areas.
  • Strengthened her role in the international academic and research community.

2015–2019 — Member of the U.S. FDA Cellular, Tissue, and Gene Therapies Advisory Committee

  • Served on the Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee.
  • Contributed scientific expertise to discussions concerning cellular and gene therapy products.
  • Participated in advisory work relevant to the safety, effectiveness, and development of advanced therapeutic technologies.

2018 — Appointed Associate Center Director for Translational Research and Innovation

  • Appointed Associate Center Director for Translational Research and Innovation at the George Washington Cancer Center.
  • Took on responsibilities supporting the development of clinical and translational research programs.
  • Helped advance efforts to bring innovative cellular therapies from laboratory research into clinical practice.
  • Supported the expansion of immunotherapy research beyond pediatric cancer into adult cancer care.

2019 — Contributed to National Cancer Research and Regulatory Advisory Activities

  • Completed a six-year term on the National Cancer Institute's Clinical Oncology Study Section.
  • Became a member of the Frederick National Laboratory Advisory Committee.
  • Served as an ad hoc member of the FDA's Pediatric Oncologic Drugs Advisory Committee.
  • Continued contributing scientific expertise to cancer research evaluation and the development of new therapeutic approaches.

2020 — Appointed President-Elect of the Foundation for the Accreditation of Cellular Therapy

  • Selected as president-elect of FACT.
  • Prepared to assume the organization's presidency, building on her previous board service.
  • Continued supporting quality standards and the responsible development of cellular therapies.

2020 — Expanded Research into Cellular Therapies for Viral Infections

  • Contributed to research involving virus-specific T cells for the prevention and treatment of infections in immunocompromised patients.
  • Supported investigations into cellular approaches targeting infections associated with transplantation.
  • Her laboratory's work also contributed to the development of SARS-CoV-2-specific T cells for potential therapeutic use in vulnerable patient populations.

January 2021 — Became President of FACT

  • Began serving as president of the Foundation for the Accreditation of Cellular Therapy.
  • Assumed a leadership role in an organization dedicated to accreditation and quality standards in cellular therapy.
  • Contributed to broader efforts to support the safe and effective delivery of cellular therapy services.

Fall 2021 — Became Editor-in-Chief of Blood Advances

  • Began serving as editor-in-chief of Blood Advances.
  • Took on editorial leadership responsibilities for a peer-reviewed journal covering hematology and related biomedical research.
  • Continued supporting the publication and evaluation of scientific advances in blood disorders, immunology, and therapeutic development.

2021–2023 — Advanced Research into Cancer and HIV Immunotherapy

  • Continued leading research into cellular therapies for cancer, viral infections, and immune deficiencies.
  • Advanced investigations into T-cell-based strategies for EBV-associated malignancies and HIV.
  • Supported translational research exploring how cellular therapies might provide treatment options for patients with limited alternatives.
  • Continued contributing to clinical trials and collaborative research programs.

February 2025 — Appointed Senior Vice President and Chief Research Officer

  • Children's National Hospital announced her appointment as Senior Vice President and Chief Research Officer of the Children's National Research Institute on February 20, 2025.
  • Assumed leadership responsibilities for growing basic and translational research programs.
  • Took responsibility for research strategy, institutional partnerships, and external research relationships.
  • Continued directing the Center for Cancer and Immunology Research.

2025–2026 — Continued Leadership in Pediatric and Translational Research

  • Continued leading research programs focused on cancer immunotherapy, cell and gene therapies, and immune deficiencies.
  • Maintained her academic appointments at George Washington University.
  • Continued supporting clinical investigations designed to translate laboratory discoveries into potential treatments.
  • Sustained her involvement in advancing cellular therapies for cancer and virus-associated diseases.

Major Achievements and Professional Recognition

1. Senior Vice President and Chief Research Officer, Children's National Hospital

Appointed in 2025, Dr. Bollard assumed a senior institutional leadership role overseeing research strategy and the development of basic, translational, and clinical research programs.

2. Director of the Center for Cancer and Immunology Research

Leads research programs focused on cancer, immunology, cellular therapies, and diseases affecting immune function.

3. Pioneer in Virus-Specific T-Cell Therapy

Has contributed to the development and clinical investigation of T-cell therapies targeting viruses associated with serious complications after stem cell transplantation and in immunocompromised patients.

4. Contributions to Pediatric Cancer Immunotherapy

Has helped advance research into cellular therapies designed to treat pediatric cancers, including virus-associated malignancies and selected blood cancers.

5. President of the Foundation for the Accreditation of Cellular Therapy

Led an organization focused on standards and accreditation in cellular therapy, supporting quality and safety in this evolving therapeutic field.

6. Past President of the International Society for Cell & Gene Therapy

Held a prominent leadership position in an international professional organization dedicated to advancing cellular and gene therapies.

7. Editor-in-Chief of Blood Advances

Led the editorial direction of a major hematology research journal beginning in fall 2021.

8. More Than 200 Peer-Reviewed Publications

Has authored or co-authored more than 200 peer-reviewed publications, contributing to research in immunology, hematology, cancer treatment, and cellular therapy.

9. Contributions to National Research and Regulatory Advisory Committees

Served on committees associated with the FDA and National Cancer Institute, contributing scientific expertise to cancer research and cellular and gene therapy discussions.

10. Translational Research Leadership at George Washington University

Helped establish and develop programs aimed at moving innovative immunotherapy research from the laboratory into clinical studies.

Institutional Affiliations

Children's National Hospital, Washington, D.C.

  • Senior Vice President and Chief Research Officer.
  • Director of the Center for Cancer and Immunology Research.
  • Member of the Division of Blood and Marrow Transplantation.

George Washington University School of Medicine and Health Sciences

  • Professor of Pediatrics.
  • Professor of Microbiology, Immunology and Tropical Medicine.
  • Dr. Robert J. and Florence T. Bosworth Distinguished Professor of Cancer and Transplantation Biology Research.
  • Associate Center Director for Translational Research and Innovation at the George Washington Cancer Center.

Foundation for the Accreditation of Cellular Therapy

  • Past President.

International Society for Cell & Gene Therapy

  • Past President.

Children's Oncology Group

  • Former Chair of the Non-Hodgkin Lymphoma Committee, 2012–2020.

Journal Blood Advances

  • Former Editor-in-Chief, beginning fall 2021.

Events & Activities

Abu Dhabi Future Health Summit 2026
Oct 20, 2026
In-Person

Abu Dhabi Future Health Summit 2026

dmg events

  • CME Credits
  • Abu Dhabi National Exhibition Centre (ADNEC), Abu Dhabi
Oct 20, 2026
In-Person

Abu Dhabi Future Health Summit 2026

Free

The Abu Dhabi Future Health Summit 2026 is a premier global platform uniting researchers, policymakers, and healthcare specialists to drive transformative health innovation and accelerate collaboration for longer, healthier lives.

dmg events

  • 3 Days
  • Abu Dhabi National Exhibition Centre (ADNEC), Abu Dhabi
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education